INTRODUCTION
Follicular lymphoma (FL) is genetically characterized in most cases by the presence of the reciprocal chromosomal translocation t(14;18)(q32;q21), which results in the deregulated expression of the anti-apoptotic BCL2 oncogene under the control of the IGH enhancer region. Histological transformation of FL to high-grade lymphoma occurs in 2% of cases each year in the rituximab era. 1 The majority of FLs transform to diffuse large B-cell lymphoma (DLBCL).
Herein we describe an unusual FL case that transformed to plasmablastic lymphoma (PBL) with MYC gene rearrangement. To investigate the pathogenesis of PBL transformation (PBL-T) in this case, especially the role of additional MYC rearrangement, we performed three-color FISH analysis.
We revealed the genetic heterogeneity of the transformed PBL tumor and, surprisingly, of the preceding FL tumor.
CASE REPORT
A 59-year-old man with no history of immunodeficiency developed a fever and night sweats in January 2013. A computed tomography (CT) scan revealed an abdominal-pelvic mass and a submandibular lymphadenopathy. Laboratory evaluation showed levels of hemoglobin at 9.3 g/dl (normal range 14-18 g/dl), serum lactate dehydrogenase (LDH) at 562 IU/ml (normal range 80-200 IU/ml) and soluble interleukin-2 receptor (sIL-2R) at 12200 U/ml (normal range 145-519 U/ml). The tumors showed abnormal uptake of fluorodeoxyglucose (FDG) on positron emission tomography Transformation of double-hit follicular lymphoma to plasmablastic lymphoma: a partial role of MYC gene rearrangement Mikiko Ise, 1) ,2) Hajime Kageyama, 3) Dai Ikebe, 3),4) Akinobu Araki, 3) Kyoya Kumagai, 1) Makiko Itami 3) Follicular lymphoma (FL) is genetically characterized by BCL2/IGH translocation. Some FL cases histologically transform to high-grade lymphoma, and the majority of cases transform to diffuse large B-cell lymphoma. We report herein an unusual FL case that transformed to plasmablastic lymphoma (PBL) with MYC gene rearrangement as early as 12 months after FL diagnosis. IGH/MYC translocation, the most common cytogenetic abnormality seen in de novo PBL, was also detected in the transformed tumor (double-hit lymphoma). The patient became resistant to chemotherapy and died 4 months after transformation. We speculate that the "second hit" of MYC rearrangement played a crucial role in PBL transformation (PBL-T) in this case. Fig. 2A, B) . The tumor cells were positive for CD20, CD79a, CD10 and BCL2 ( Fig. 2C-F hybridization (FISH) analysis demonstrated BCL2/IGH fusion signals in 54.0% of analyzed cells (Table 1) . A diagnosis of FL grade 2 was made. Bone marrow involvement was also demonstrated (stage IVB, FLIPI: high). The FL was with high tumor burden meeting the GELF criteria: a diameter of abdominal tumor mass was over 7cm, and the patient presented B symptoms (a fever and night sweats). In September 2013, after eight cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone), the tumor was significantly decreased (partial remission) (Fig. 1B) . Serum sIL-2R levels were decreased to 500 U/ml. Rituximab maintenance was not performed because it was not covered by health insurance. In January 2014, at 12 months after the initial FL diagnosis, Fig. 3 . A. Cytology of pleural effusion in January 2014 showed large neoplastic plasmacytoid cells with abundant cytoplasm and eccentrically located round nuclei with prominent nucleoli (Wright-Giemsa, ×600). B-J. Histological and immunophenotypic findings of plasmablastic lymphoma. Sections of abdominal lymph node in January 2014 showed a diffuse proliferation of immunoblastic and plasmablastic cells (hematoxylin and eosin) (B, ×40 and C, ×400). The tumor cells lacked CD20 (D, ×400) and CD10 (E, ×400), and expressed BCL2 (F, ×400), CD38 (G, ×400) and CD138 (H, ×400). The tumor cells lacked kappa (I, ×400) and lambda (J, ×400). The Ki-67 proliferation index was 90% (K, ×400 (Fig. 1C) . Pleural effusion cytology showed large abnormal lymphoid cells with plasmablastic features: round eccentric nuclei, prominent nucleoli and abundant basophilic cytoplasm (Fig.  3A ). An abdominal mass needle biopsy also revealed a diffuse proliferation of immunoblastic and plasmablastic cells (Fig. 3B, C) . The tumor cells were negative for CD20 (Fig.  3D ), CD79a, PAX5 and TdT (data not shown), weakly positive for CD10 (Fig. 3E ) and positive for BCL-2 ( Fig. 3F) 3L) . IGH/MYC fusion signals, the most common translocation detected in de novo PBL, 2 was also demonstrated in 12.0% of the cells (i.e. double-hit lymphoma) (Fig. 3M) ( Table 1 ). The patient died of disease 16 months after FL diagnosis and 4 months after PBL-T. In autopsy, the PBL tumor replaced mesenterium, retroperitoneal and pelvic space and involved the pancreas, adrenal glands, right kidney and duodenum. Histological and immunophenotypic findings were the same as that of abdominal mass in January 2014. No residual FL population was identified.
POLYMERASE CHAIN REACTION, SEQUENCING, AND FISH ANALYSIS
Molecular studies and interphase FISH analysis were performed on FL and PBL specimens. For FL, the submandibular lymph node biopsy specimen from February 2013 was used. For PBL, because only few numbers of cells were available in the abdominal mass needle biopsy and pleural effusion cell block specimens from January 2014, the abdominal mass specimen from May 2014 autopsy was used.
Polymerase chain reaction analysis for BCL/IGH was performed on DNA extracted from frozen sections using established BIOMED-2 consensus primers. 3 The result yielded clonal rearrangements at the major breakpoint region with identical migration patterns in the FL and PBL, suggesting that these two neoplasms were clonally related (Fig. 4A) . Sequencing of the amplicons showed an identical junction sequence consisting of the BCL2 sequence from the 3' untranslated region in exon 3 and the JH6 sequence (Fig.  4B) , confirming that the two tumors are the identical neoplastic clone.
To investigate the pathogenesis of PBL-T in this case, especially the role of additional MYC gene rearrangement, we performed three-color FISH analysis on the PBL stamp preparations. A cocktail of chemically synthesized singlecolor dual-fusion FISH probes (SureFISH; Agilent Technologies, TX, USA) were used: red-labeled BCL2, green-labeled IGH and aqua-labeled MYC. We identified the presence of BCL2/IGH/MYC triple fusion signals on a single chromosome ( Fig. 5A ; white arrows), but BCL2/IGH ( Fig.  5A, B ; orange arrows) and IGH/MYC ( Fig. 5A, C ; blue arrows) fusion signals also coexisted in a single nucleus. Therefore, we retrospectively performed FISH analysis on the FL stamp preparations. Surprisingly, aberrant BCL2/ IGH/MYC (26% of the interphase nuclei evaluated) ( Fig. 6A ; white arrow) and IGH/MYC fusion signals (45%) (Fig. 6A,  C ; blue arrows) were detected, concurrent with typical BCL2/ IGH fusion signals (94%) (Fig. 6A, B ; orange arrows) (i.e. double-hit lymphoma).
DISCUSSION
Although FL is a clinically indolent disease, transformed FL is usually characterized by an aggressive course, poor response to chemotherapy and short survival. 1, 4 The median overall survival following transformation in patients with transformation within 18 months of FL diagnosis was inferior compared with patients with a later transformation. 1 The present case transformed to PBL as early as 12 months after FL diagnosis and died of the disease 4 months after transformation.
FL transformation to high-grade lymphoma occurs by divergent rather than direct clonal evolution. Most genetic alterations typical of transformed FL can be found at a lower prevalence in indolent FL, suggesting that a single alteration may not be sufficient to drive transformation. 4 Detailed genetic analyses have revealed several discrete mechanisms driving transformation. 5 Alteration of genes deregulating cell cycle progression and the DNA damage response (CDKN2A/B, MYC and TP53) have been frequently observed in transformed FL, suggesting that the loss of genetic stability and deregulated proliferation are critical steps in transformation. 5 MYC deregulation is implicated in 20% of all human malignancies and is often associated with poor prognosis. 7 DHL is characterized by a rapidly progressing clinical course that is refractory to aggressive treatment and has a short survival time. 8 In addition to de novo disease, DHL occurs in the setting of transformation of indolent lymphoma, particularly FL, when the BCL2/IGH lymphoma acquires MYC translocation, 9 as is the present case.
PBL is an uncommon subtype of DLBCL that shows diffuse proliferation of large neoplastic cells resembling immunoblasts and plasmablasts. PBL is clinically characterized by an aggressive course and high rates of relapse. The most common cytogenetic abnormality seen in PBL is IGH/MYC translocation. 2 Most PBL cases are EBV-associated, with a high proliferation index. Our PBL-T case carried IGH/MYC translocation and a high Ki-67 proliferation index but was negative for EBV.
PBL-T of FL is extremely rare, and only four cases have been reported (Table 2) . 10, 11 Only one case displayed MYC gene rearrangement. 10 The other three cases without MYC rearrangement (cases 2, 3 and 4) achieved complete remission with R-CHOP and remained disease free for 10 to 24 months. 11 One case with MYC rearrangement (case 1) was chemotherapy-resistant and died of disease less than 6 months after PBL-T. 10 In that case, Ouansafi et al. identified MYC gene rearrangement in almost all nuclei of the PBL-T tumor using FISH analysis, although the partner gene was not shown. The authors also demonstrated that the PBL-T tumor exhibited a much lower intra-clonal diversity compared with the preceding FL tumor by somatic hypermutation analysis. No MYC rearrangement was detected in the preceding FL tumor. 10 The present case is the second case of PBL-T of FL with MYC gene rearrangement. We provide definitive evidence of histological transformation by demonstrating identical BCL2/ IGH gene breakpoints in both PBL and FL. Conventional FISH analysis detected IGH/MYC fusion signals in addition to BCL2/IGH in the PBL-T tumor (Fig. 3L, M) (i.e. DHL). Taking the case of Ouansafi into consideration, we speculated that the "second hit" of MYC rearrangement played a crucial role in PBL-T in the current case. However, in contrast with previous case, the chromosome copy number increased in the current case and the karyotype became complex. Threecolor FISH analysis demonstrated the presence of BCL2/ IGH/MYC triple fusion signals on a single chromosome, as we expected ( Fig. 5A ; white arrows), but BCL2/IGH (Fig.  5A, B ; orange arrows) and IGH/MYC (Fig. 5A, C ; blue arrows) fusion signals coexisted in a single nucleus. Remarkably, the PBL-T tumor was genetically heterogeneous, despite being histologically quite homogeneous PBL. We also retrospectively performed triple fusion FISH analysis on the FL specimen. Surprisingly, the FL tumor was also genetically heterogeneous harboring aberrant BCL2/IGH/ MYC ( Fig. 6A ; white arrow) and IGH/MYC fusion signals ( Fig. 6A,C ; blue arrows) in addition to typical BCL2/IGH fusion signals (Fig. 6A, B ; orange arrows) (i.e. DHL), despite being histologically quite homogeneous FL. This indicates that the preceding FL tumor was already genetically heterogeneous and genomically instable. This would contribute to such an early transformation to high-grade lymphoma, PBL. This also suggests that the role of MYC rearrangement was partial in PBL-T in this case; MYC dysregulation might be a necessary condition for PBL-T but not sufficient to allow PBL-T. Other mechanisms such as multiple chemotherapeutic agents and other genetic alterations will contribute to PBL-T and poor outcome. In future studies, we will isolate genetically heterogeneous FLs at diagnosis using this simple three-color FISH technique and consider applying aggressive induction regimens to improve patient outcomes.
In summary, we reported an unusual case of FL transformed to PBL with MYC gene rearrangement. Using a highly specific three-color FISH technique, we demonstrated that the PBL-T tumor was genetically heterogeneous harboring BCL2/IGH, IGH/MYC and BCL2/IGH/MYC translocations simultaneously. Moreover, we revealed that the preceding FL tumor was also genetically heterogeneous, despite being histologically quite homogeneous FL. This suggests that the role of MYC dysregulation was partial in PBL-T. Genetic instability including MYC dysregulation in the preceding FL tumor would contribute to PBL-T and poor outcome in this case. This study will broaden our understanding the pathogenesis of high-grade transformation of FL and help to improve patient outcome.
